Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

156.34 +4.53 (+2.99%)
Streaming Delayed Price Updated: 2:01 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
News headline image
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Michael Elliott Named to 2022 Empower Advocate Executive Role Model List.
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
From Gilead Sciences, Inc.
Via Business Wire
News headline image
4 Questions With Betty Chiang: Addressing Health Disparities in the Asian Community
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Portugal's Positive Approach to Teaching Teens about the Birds, Bees and STIs
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead at Forefront of Herculean Effort to Combat COVID-19
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Living with Metastatic Bladder Cancer: Joey's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Product Recall
News headline image
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
From Gilead Sciences, Inc.
Via Business Wire
News headline image
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Closing the Representation Gap in Schools, One Black Male Teacher at a Time
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Product Recall
News headline image
Opinion: The Road to Ending Visceral Leishmaniasis
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027 Bio-based Platform Chemicals Market Overview The Bio-based Platform Chemicals Market size is forecast to reach... 
Via iCrowdNewswire
Topics Derivatives
News headline image
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
News headline image
On Earth Day, Gilead Marks Strides in Environmental Sustainability
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Emissions
News headline image
Gilead Sciences Announces First Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey
SOURCE: Gilead Sciences 
Via 3BL Media
News headline image
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
From Gilead Sciences, Inc.
Via Business Wire
News headline image
The Translatinx Network Helps a Resilient Community 'Live Its Truth'
SOURCE: Gilead Sciences 
Via 3BL Media
Tour for Diversity in Medicine, Gilead Sciences and the Advisory Group to SHC Vaccine Equity Program to Receive Booker T. Washington Award From National Minority Quality Forum
SOURCE: Gilead Sciences 
Via 3BL Media
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.